Cells, Free Full-Text

Immunometabolism is an emerging discipline in cancer immunotherapy. Tumor tissues are heterogeneous and influenced by metabolic reprogramming of the tumor immune microenvironment (TIME). In the TIME, multiple cell types interact, and the tumor and immune cells compete for limited nutrients, resulting in altered anticancer immunity. Therefore, metabolic reprogramming of individual cell types may influence the outcomes of immunotherapy. Understanding the metabolic competition for access to limited nutrients between tumor cells and immune cells could reveal the breadth and complexity of the TIME and aid in developing novel therapeutic approaches for cancer. In this review, we highlight that, when cells compete for nutrients, the prevailing cell type gains certain advantages over other cell types; for instance, if tumor cells prevail against immune cells for nutrients, the former gains immune resistance. Thus, a strategy is needed to selectively suppress such resistant tumor cells. Although challenging, the concept of cell type-specific metabolic pathway inhibition is a potent new strategy in anticancer immunotherapy.

THE LIVES OF A CELL : LEWIS THOMAS : Free Download, Borrow, and Streaming : Internet Archive

Serial Number Alcohol 120 1.9 6 - Colaboratory

Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity - ScienceDirect

Amyloid β directly interacts with NLRP3 to initiate inflammasome activation: identification of an intrinsic NLRP3 ligand in a cell-free system, Inflammation and Regeneration

JCM, Free Full-Text

Cells, Free Full-Text

Cell-free synthesis of human interferon. - Abstract - Europe PMC

Rapid cell-free forward engineering of novel genetic ring oscillators

Effect of calendar ageing on the cycle life of anode-free full-cells.

Cells, Free Full-Text

Sequencing of Circulating Cell-free DNA during Pregnancy

Fat extract promotes angiogenesis in a murine model of limb ischemia: a novel cell-free therapeutic strategy, Stem Cell Research & Therapy

Full-spectrum cell-free RAN for 6G systems: s